{
  "ticker": "LLY",
  "target_date": "2025-01-23",
  "actual_date": "2025-01-23",
  "collected_at": "2025-12-08T11:18:52.741617",
  "price": {
    "open": 742.12,
    "high": 760.92,
    "low": 738.74,
    "close": 760.9242553710938,
    "volume": 3127200,
    "change_1d_pct": 1.67,
    "change_7d_pct": -3.87,
    "change_30d_pct": -7.27
  },
  "technicals": {
    "rsi_14": 48.66,
    "sma_20": 766.09,
    "sma_50": 774.35,
    "macd": -10.286,
    "macd_signal": -9.117,
    "macd_histogram": -1.169,
    "bb_upper": 808.24,
    "bb_lower": 723.94,
    "price_vs_sma20_pct": -0.67,
    "price_vs_sma50_pct": -1.73,
    "volume_ratio": 0.88
  },
  "fundamentals": {
    "market_cap": 889764708352,
    "pe_ratio": 48.629837,
    "forward_pe": 43.80119,
    "price_to_book": 37.36954,
    "price_to_sales": 14.974213,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.74,
    "pct_from_52w_low": 59.12
  },
  "macro": {
    "spy": {
      "price": 604.45,
      "change_1d_pct": 0.55,
      "change_7d_pct": 4.73
    },
    "vix": {
      "level": 15.02,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.64
    },
    "dollar_index": {
      "level": 108.05
    },
    "gold": {
      "price": 2763.1
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
      "source": "SeekingAlpha",
      "datetime": 1737639382,
      "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company\u00e2\u0080\u0099s future looks bright.",
      "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556"
    },
    {
      "headline": "Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement",
      "source": "Finnhub",
      "datetime": 1737626468,
      "summary": "INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a...",
      "url": "https://finnhub.io/api/news?id=3c7cea1c1cef589c49402f3d7d74d38f6b3e8ea11281e302ac925c9a4146027d"
    },
    {
      "headline": "Viking Therapeutics: Investors Meeting Reality Of The Obesity Market",
      "source": "SeekingAlpha",
      "datetime": 1737623700,
      "summary": "Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.",
      "url": "https://finnhub.io/api/news?id=d36aded5203105df503d71a1d2d3006d6a7ce702ed2960f15d68ee186d862f6f"
    },
    {
      "headline": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
      "source": "MarketWatch",
      "datetime": 1737617880,
      "summary": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
      "url": "https://finnhub.io/api/news?id=2f6820a2147d9f0ededc7d79480289e92373f4bd56224d7b19884db488c34ec8"
    },
    {
      "headline": "Beyond Big Tech: 20 stocks to ride the AI trend",
      "source": "MarketWatch",
      "datetime": 1737548760,
      "summary": "Beyond Big Tech: 20 stocks to ride the AI trend",
      "url": "https://finnhub.io/api/news?id=6b1766ad4fcce95a7f1d70daf2be0b5bf09974b7c2a316ef481a77bb94667cbc"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667469.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000016/xslF345X05/wk-form4_1737667469.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667411.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000014/xslF345X05/wk-form4_1737667411.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000012/xslF345X05/wk-form4_1737667361.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667303.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000010/xslF345X05/wk-form4_1737667303.xml"
    },
    {
      "form": "4",
      "date": "2025-01-23",
      "description": "xslF345X05/wk-form4_1737667237.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000008/xslF345X05/wk-form4_1737667237.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}